Health-Related Quality of Life With Pomalidomide plus Dexamethasone plus Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients

被引：0

作者：

Reece, Donna ^{[1
]}

Bahlis, Nizar J. ^{[1
]}

Samaras, Christy Joy ^{[1
]}

Sebag, Michael ^{[1
]}

Berdeja, Jesus ^{[1
]}

Ganguly, Siddhartha ^{[1
]}

Matous, Jeffrey ^{[1
]}

Song, Kevin ^{[1
]}

Seet, Christopher S. ^{[1
]}

Talamo, Giampaolo ^{[1
]}

Acosta-Rivera, Mirelis ^{[1
]}

Bar, Michael ^{[1
]}

Quick, Donald ^{[1
]}

Anz, Bertrand ^{[1
]}

Fonseca, Gustavo ^{[1
]}

Agarwal, Amit ^{[1
]}

Chung, Weiyuan ^{[1
]}

Zafar, Faiza ^{[1
]}

Siegel, David S. ^{[1
]}

机构：

[1] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

Pomalidomide; Quality of Life; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.457

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SP-131

引用

页码：E277 / E278

页数：2

共 50 条

[1] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen J.
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Raymond
Wang, Jianping
Nottage, Kerri
Chiu, Christopher
Khokhar, Nushmia Z.
Ahmadi, Tahamtan
Lonial, Sagar
[J]. BLOOD, 2017, 130 (08) : 974 - 981
[2] A health-related quality-of-life (HRQoL) analysis of pomalidomide plus low-dose dexamethasone plus daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
Reece, Donna Ellen
Bahlis, Nizar J.
Samaras, Christy Joy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddartha
Matous, Jeffrey
Song, Kevin W.
Seet, Christopher
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand Marquess
Fonseca, Gustavo A.
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Siegel, David Samuel DiCapua
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel
Gary J. Schiller
Christy Samaras
Michael Sebag
Jesus Berdeja
Siddhartha Ganguly
Jeffrey Matous
Kevin Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald Quick
Bertrand Anz
Gustavo Fonseca
Donna Reece
William E. Pierceall
Weiyuan Chung
Faiza Zafar
Amit Agarwal
Nizar J. Bahlis
[J]. Leukemia, 2020, 34 : 3286 - 3297
[4] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Siegel, David S.
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Pierceall, William E.
Chung, Weiyuan
Zafar, Faiza
Agarwal, Amit
Bahlis, Nizar J.
[J]. LEUKEMIA, 2020, 34 (12) : 3286 - 3297
[5] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
Moustafa, Muhamad Alhaj
Parrondo, Ricardo
Abdulazeez, Mays F.
Roy, Vivek
Sher, Taimur
Alegria, Victoria R.
Warsame, Rahma M.
Larsen, Jeremy
Gonsalves, Wilson I.
Kourelis, Taxiarchis
Kapoor, Prashant
Fonseca, Rafael
Buadi, Francis K.
Dingli, David
Hayman, Suzanne R.
Reeder, Craig B.
Agrawal, Arshi
Chanan-Khan, Asher A.
Ailawadhi, Sikander
[J]. BLOOD, 2020, 136
[6] Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Agarwal, Amit
Chung, Weiyuan
Zafar, Faiza
Bahlis, Nizar
[J]. BLOOD, 2018, 132
[7] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study
Houghton, Katherine
Dimopoulos, Meletios A.
Lin, Peggy
Guillonneau, Sophie
Bury, Denise
Attal, Michel
Richardson, Paul G.
Delforge, Michel
[J]. BLOOD, 2019, 134
[8] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Plesner, Torben
Dimopoulos, Meletios A.
Oriol, Albert
San-Miguel, Jesus
Bahlis, Nizar J.
Rabin, Neil
Suzuki, Kenshi
Yoon, Sung-Soo
Ben-Yehuda, Dina
Cook, Gordon
Goldschmidt, Hartmut
Grosicki, Sebastian
Qin, Xiang
Fastenau, John
Garvin, Wendy
Carson, Robin
Renaud, Thomas
Gries, Katharine S.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139
[9] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Dimopoulos, Meletios
Spencer, Andrew
Attal, Michael
Prince, H. Miles
Harousseau, Jean-Luc
Dmoszynska, Anna
San Miguel, Jesus
Hellmann, Andrzej
Facon, Thierry
Foa, Robin
Corso, Alessandro
Masliak, Zvenyslava
Olesnyckyj, Marta
Yu, Zhinuan
Patin, John
Zeldis, Jerome B.
Knight, Robert D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21): : 2123 - 2132
[10] Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dabkara, Deepak
Bajpai, Jyoti
[J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (03) : 10 - 13

← 1 2 3 4 5 →